Healthy volunteers test new nerandomilast formulation and food effects

NCT ID NCT06624072

First seen Jun 25, 2026 · Last updated Jun 25, 2026

Summary

This completed Phase 1 trial enrolled 15 healthy adults to compare two different formulations of the drug nerandomilast and to see if food affects how the new formulation is absorbed. Participants received single doses in a crossover design. The study focuses on drug levels in the blood, not on treating any disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Humanpharmakologisches Zentrum Biberach

    Biberach, 88397, Germany

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

nerandomilast (also known as BI 1015550, JASCAYD®)

What this could lead to

If successful, this study could help determine the best formulation and dosing instructions for nerandomilast, potentially improving how it is taken in future trials.

What could go wrong

This is a very early, small study in healthy volunteers, not patients. It only measures how the drug moves through the body, not whether it works for any disease. Results may not predict real-world effects.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.